Edwards Lifesciences has announced that it has completed the acquisition of BMEYE, a privately held Dutch company that specialises in the development of non-invasive technology for advanced haemodynamic monitoring. BMEYE’s technology provides continuous, real-time information to clinicians and can be used in the surgical, intensive care, emergency room and cardiology settings.
“BMEYE’s unique non-invasive technology platform complements our existing portfolio and will provide clinicians with critical, comprehensive haemodynamic monitoring information for a broader range of patients. Numerous studies have concluded that therapy guided by haemodynamic monitoring improves patient outcomes and reduces complications and lengths of hospital stays,” said Carlyn Solomon, Edwards’ corporate vice president, critical care and vascular. “This acquisition supports our ongoing commitment to build and strengthen our offerings for clinicians and patients, and reinforces our leadership in haemodynamic monitoring.”
BMEYE’s monitoring products work with a non-invasive finger cuff to measure continuous, real-time information on cardiac output, blood pressure, fluid responsiveness and other important haemodynamic parameters. Currently, BMEYE’s products are approved for sale in the United States, throughout Europe and in several other countries.
Rob de Ree, chief executive officer of BMEYE said, “BMEYE has a solid history of developing innovative haemodynamic monitoring solutions. We look forward to joining the Edwards team to extend the reach of our existing products, and to continue to develop novel technologies to help clinicians and improve patient care worldwide.”
While BMEYE’s products have primarily been used by clinicians outside of the hospital, over the next 18 months, Edwards plans to further develop BMEYE’s technology and integrate it into the Edwards EV1000 clinical platform for use in the acute care setting in hospitals.
The purchase price was €32.5 million (approximately US$42 million). Edwards expects the net earnings impact from this transaction to be immaterial in 2012, and slightly dilutive in 2013. Additional details will be forthcoming when the company provides 2013 financial guidance in December.
